Data / Form D filings / Mangrove Therapeutics Inc.
Mangrove Therapeutics Inc.: Form D filing
Mangrove Therapeutics Inc., a biotechnology company in Sacramento, CA, filed a Form D with the SEC in 2026. The latest, on July 31, 2026, reports $2.5 million sold of a $5 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2108 N ST STE C, Sacramento, CA, 95816
- Phone
- (650) 485-3618
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2025
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2111089
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | New notice | $5,000,000 | $2,455,000 | $2,545,000 | 9 | Jul 21, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jin Li | Director | |
| Benjamin Zhiyi Chen | Executive Officer, Director | Chief Executive Officer (Interim) / President |
| Alexander Simon Green | Executive Officer | Chief Financial Officer Treasurer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jul 27, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Mangrove Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.